TERM LOAN AGREEMENT, dated as of July 14, 2017 among STRONGBRIDGE U.S. INC, STRONGBRIDGE BIOPHARMA PLC, CORTENDO AB (PUBL), CORTENDO CAYMAN LTD., as Borrowers, The Subsidiary Guarantors from Time to Time Party Hereto, The Lenders from Time to Time...Term Loan Agreement • July 17th, 2017 • Strongbridge Biopharma PLC • Pharmaceutical preparations • New York
TERM LOAN AGREEMENT, dated as of July 14, 2017 (this “Agreement”), among STRONGBRIDGE U.S. INC., a Delaware corporation (“Lead Borrower”), STRONGBRIDGE BIOPHARMA PUBLIC LIMITED COMPANY, a public limited company incorporated under the laws of Ireland (“Parent”), CORTENDO CAYMAN LTD., an exempted company incorporated in the Cayman Islands (“Cayman Borrower”), CORTENDO AB (PUBL), a public limited liability company incorporated under the laws of Sweden with registration number 556537-6554 (“Swedish Borrower” and together with the Lead Borrower, Parent, Cayman Borrower, and each other Person that becomes, or is required to become, a “Borrower” after the date hereof pursuant to Section 8.12(a) or (b), each a “Borrower” and collectively, “Borrowers”), the Subsidiary Guarantors from time to time party hereto, the Lenders from time to time party hereto and CRG SERVICING LLC, a Delaware limited liability company (“CRG Servicing”), as administrative agent and collateral agent for the Lenders (in
AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 17th, 2017 • Strongbridge Biopharma PLC • Pharmaceutical preparations • New York
THIS AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT (the “Amendment”), dated as of July 13, 2017, is entered into by and among Strongbridge Biopharma plc, an Irish public limited company (the “Company”), and each person identified on the signature pages hereto (such persons, the “Amending Purchasers”). This Amendment amends certain provisions under that certain Securities Purchase Agreement, dated as of December 22, 2016 (the “Securities Purchase Agreement”), by and among the Company and each Purchaser (as defined therein). Capitalized terms used in this Amendment not otherwise defined herein shall have the meanings ascribed to such terms in the Securities Purchase Agreement.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 17th, 2017 • Strongbridge Biopharma PLC • Pharmaceutical preparations • Texas
This Securities Purchase Agreement (this “Agreement”) is dated as of July 14, 2017 by and between Strongbridge Biopharma plc, an Irish public limited company (the “Company”), and CRG Partners III L.P., CRG Partners III — Parallel Fund “A” L.P., CRG Partners III - Parallel Fund “B” (Cayman) L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III (Cayman) Unlev AIV I L.P. (collectively, the “Purchaser”).
WARRANT TO PURCHASE ORDINARY SHARES OF STRONGBRIDGE BIOPHARMA PLC Dated as of July 14, 2017 (the “Issue Date”) Void after the date specified in Section 8Strongbridge Biopharma PLC • July 17th, 2017 • Pharmaceutical preparations • New York
THIS CERTIFIES THAT, for value received, [NAME]., or its registered assigns (the “Holder”), is entitled, subject to the provisions and upon the terms and conditions set forth herein, to purchase from STRONGBRIDGE BIOPHARMA PLC, a public limited company incorporated under the laws of Ireland (the “Company”), that number of shares (the “Shares”) of the Company’s ordinary shares, of nominal value $0.01 per share (the “Ordinary Shares”), at such times and at the price per Share, set forth in Section 1. The term “Warrant” as used herein shall include this Warrant and any warrants delivered in substitution or exchange therefor as provided herein. This Warrant is issued in connection with the transactions described in the Term Loan Agreement, dated as of July 14, 2017, by and between the Company, the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto and CRG Servicing LLC.
